Dataset Information

Does the cytokine adsorber CytoSorb^® reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study.

ABSTRACT:

Background

Hemadsorption of cytokines is used in critically ill patients with sepsis or septic shock. Concerns have been raised that the cytokine adsorber CytoSorb^® unintentionally adsorbs vancomycin. This study aimed to quantify vancomycin elimination by CytoSorb^®.

Methods

Critically ill patients with sepsis or septic shock receiving continuous renal replacement therapy and CytoSorb^® treatment during a prospective observational study were included in the analysis. Vancomycin pharmacokinetics was characterized using population pharmacokinetic modeling. Adsorption of vancomycin by the CytoSorb^® was investigated as linear or saturable process. The final model was used to derive dosing recommendations based on stochastic simulations.<

SUBMITTER: Scharf C

PROVIDER: S-EPMC9124739 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Does the cytokine adsorber CytoSorb^® reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study.

Background

Methods

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Does the cytokine adsorber CytoSorb® reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study.

Background

Methods

OmicsDI is part of the ELIXIR infrastructure

Tweets

Does the cytokine adsorber CytoSorb^® reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study.